Key result
Nonpeptide angiotensin II receptor antagonists competitively inhibited the vasoconstrictor response to angiotensin II and caused a sustained decrease in arterial pressure in animal models.
Population
Preclinical models including adrenal cortical membranes, smooth muscle cells, renal hypertensive rats, and…
Design
Preclinical
Authors
Loading...
Supports preclinical development of oral ARBs; leaves open human efficacy, safety, and translation.
This preclinical study identifies nonpeptide angiotensin II receptor antagonists as a novel and effective class of antihypertensive agents with oral bioavailability.
Timmermans et al. (2008) studied Hypertension. Nonpeptide Angiotensin II Receptor Antagonists (e.g., EXP7711) was evaluated on Vasoconstrictor response to angiotensin II and arterial pressure. Nonpeptide angiotensin II receptor antagonists competitively inhibited the vasoconstrictor response to angiotensin II and caused a sustained decrease in arterial pressure in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: